Meanwhile, CDK12 deficiency‐caused energy metabolism reprogramming may suggest targeting mitochondrial ETC as a promising efficient treatment strategy for CDK12 mutated prostate cancer patients (Figure 7). The gene discussed is CDK12; the disease is prostate carcinoma.